A Prospective, Double Blind, Randomized, Multicenter Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Patients With a Primary Diagnosis of a Depressive Disorder Versus Treatment as Usual.

Date de début de l'étude : 1 mars 2013

Inclusion Criteria: Must speak and read English Must be able to provide written informed consent A primary diagnosis of a DSM-IV depressive disorder Co-morbidities of non-psychotic behavioral disorders, including PTSD and mild Traumatic Brain Injury (mTBI) are eligible to participate. Able to stop all medications (wash out) for 5 half-lves of all medication(s) which affect the EEG. Outpatient subjects are eligible if they can be washed out of their medications in 14 days or less. Ability to comply with the requirements of the study Exclusion Criteria: Diagnosis of a psychotic disorder History of, or current, open head trauma Subjects who would not be good candidates to be washed out of their medications, in the opinion of the investigator. History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months. Clinically significant medical illness, including thyroid disorders. Participation in any other therapeutic drug study within 60 days preceding inclusion in the study. Know pregnancy and/or lactation, or intent to become pregnant during the study. Chronic or acute pain requiring prescription medication(s). Candidates with any metal, shrapnel or other similar objects in the head that could affect the QEEG Candidates that are currently stable and considered to be at maximum medical improvement on current medications.